Legend Biotech Corporation
LEGN
$34.18
-$0.52-1.50%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -588.73% | 69.57% | 58.71% | -132.80% | 68.76% |
| Total Depreciation and Amortization | 3.10% | 3.43% | -0.66% | 4.22% | 0.89% |
| Total Amortization of Deferred Charges | -14.21% | -58.64% | 83.61% | -3.41% | 326.50% |
| Total Other Non-Cash Items | 32,597.88% | 99.48% | -166.14% | 4,527.90% | -101.01% |
| Change in Net Operating Assets | -253.05% | -89.30% | 1,018.04% | -351.82% | 90.41% |
| Cash from Operations | -4,492.49% | -110.64% | 116.22% | -57.19% | 37.64% |
| Capital Expenditure | 39.57% | 45.28% | -43.73% | 19.19% | 11.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 147.84% | -77.53% | -194.67% | 302.19% | -76.30% |
| Cash from Investing | 147.31% | -75.60% | -197.21% | 294.91% | -71.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -0.34% | -53.03% | -349.34% | 117.66% | -12.93% |
| Issuance of Common Stock | 155.74% | 33.10% | 155.88% | -76.85% | -99.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 344.50% | 14.92% | -10.16% | -3.75% | -99.88% |
| Foreign Exchange rate Adjustments | 5,722.22% | 102.62% | -123.59% | 285.46% | -133.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 137.06% | -83.17% | -220.97% | 216.50% | -147.06% |
